Merrimack Pharmaceuticals Inc. (MACK)
US Market

Merrimack Pharmaceuticals Stock Price & Analysis


MACK Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.56 - $7.41
Previous Close$3.7
Average Volume (3M)29.64K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$13.36M
Total Debt (Recent Filing)$0.00
P/E Ratio-30.8
Next EarningsNov 09, 2022
EPS EstimateN/A
Dividend YieldN/A
1Y Price TargetN/A
EPS (TTM)-0.12
Shares Outstanding13,410,243
Standard Deviation0.20
10 Day Avg. Volume21,757
30 Day Avg. Volume29,635
P/B Ratio3.71
P/S RatioN/A
P/CF RatioN/A
P/FCF Ratio-24.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Merrimack Pharmaceuticals’s price range in the past 12 months?
Merrimack Pharmaceuticals lowest stock price was $3.56 and its highest was $7.41 in the past 12 months.
    What is Merrimack Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Merrimack Pharmaceuticals’s upcoming earnings report date?
    Merrimack Pharmaceuticals’s upcoming earnings report date is Nov 09, 2022 which is in 44 days.
      How were Merrimack Pharmaceuticals’s earnings last quarter?
      Merrimack Pharmaceuticals released its earnings results on Aug 04, 2022. The company reported -$0.036 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.036.
        Is Merrimack Pharmaceuticals overvalued?
        According to Wall Street analysts Merrimack Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Merrimack Pharmaceuticals pay dividends?
          Merrimack Pharmaceuticals pays a Notavailable dividend of $0.5 which represents an annual dividend yield of N/A. Merrimack Pharmaceuticals’s last Notavailable dividend payment was on Dec 23, 2019. Merrimack Pharmaceuticals’s upcoming ex-dividend date is Dec 13, 2019
            What is Merrimack Pharmaceuticals’s EPS estimate?
            Merrimack Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Merrimack Pharmaceuticals have?
            Merrimack Pharmaceuticals has 13,410,243 shares outstanding.
              What happened to Merrimack Pharmaceuticals’s price movement after its last earnings report?
              Merrimack Pharmaceuticals reported an EPS of -$0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.93%.
                Which hedge fund is a major shareholder of Merrimack Pharmaceuticals?
                Among the largest hedge funds holding Merrimack Pharmaceuticals’s share is Western Standard Llc. It holds Merrimack Pharmaceuticals’s shares valued at 8M.


                  Merrimack Pharmaceuticals Stock Analysis

                  Smart ScoreNeutral
                  The Merrimack Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Merrimack Pharmaceuticals Inc.

                  Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.

                  Similar Stocks
                  Price & Change
                  Gilead Sciences
                  Vertex Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis